Agomab Therapeutics NV
SEC CIK 2020932 · AGMB · last insider filing 2026-03-18
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Epstein David R | Director | filed 2026 - 2026 |
| Verduyn-van Weegen Felice Isabel | Director | filed 2026 - 2026 |
| Jahreis Angelika Martha | Director | filed 2026 - 2026 |
| Hammer Ohad | Director | filed 2026 - 2026 |
| Bond Colin Michael | Director | filed 2026 - 2026 |
| Knotnerus Tim Jasper | Director · Chief Executive Officer | filed 2026 - 2026 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Lefever Ellen | General Counsel | filed 2026 - 2026 |
| Borderias Andrea Saez | Chief Development Officer | filed 2026 - 2026 |
| Kemula Pierre Thadee Victor | Chief Financial Officer | filed 2026 - 2026 |
| van der Horst Paul Henryk | Chief Business Officer | filed 2026 - 2026 |
| Wiesel Philippe Constantin | Chief Medical Officer | filed 2026 - 2026 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.